Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01254604
First received: December 3, 2010
Last updated: October 9, 2014
Last verified: October 2014

December 3, 2010
October 9, 2014
December 2011
May 2013   (final data collection date for primary outcome measure)
  • Mean Diurnal IOP Change From Baseline at Week 4 - Study Eye [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
    IOP was measured at baseline, Week 2 and Week 4 using a Goldmann applanation tonometer. At each of these visits, IOP measurement was performed at 0800, 1000 and 1600 hours. At each IOP assessment time point during a visit, 2 consecutive IOP measurements were made. If these 2 measurements differed by ≤2 mmHg, then the average of the 2 IOP values was recorded. If the 2 measurements differed by >2 mmHg, then a third measurement was obtained and the median of these 3 measurements was recorded. The IOP value for a visit (e.g., Week 4) was the mean of the values recorded at the 3 time points during the visit. For each participant, one "study eye" was identified for data summarization and analysis for this primary efficacy outcome measure. The "study eye" was the eye with the higher (i.e., "worse") IOP at baseline, or if both eyes had the same baseline IOP value, the right eye was designated the "study eye." Change from baseline in IOP at Week 4 = Week 4 IOP value − baseline IOP value.
  • Number of Participants With an Adverse Event (AE) [ Time Frame: Up to 14 days after Week 4 visit ] [ Designated as safety issue: Yes ]
    An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. Participants with one or more AEs during the study are counted once in this summary.
  • Number of Participants Who Discontinued Study Drug Due to an AE [ Time Frame: Up to Week 4 ] [ Designated as safety issue: Yes ]
    An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. Participants who discontinued study drug treatment due to an AE are counted once in this summary.
Mean diurnal change in IOP from baseline and Week 4 [ Time Frame: From baseline to Week 4 ] [ Designated as safety issue: No ]
Application of one drop of the medications in the morning and one drop in the evening for four weeks
Complete list of historical versions of study NCT01254604 on ClinicalTrials.gov Archive Site
Number of Participants With ≥25% Reduction in IOP From Baseline to Week 4 - Study Eye [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
IOP was measured at baseline, Week 2 and Week 4 using a Goldmann applanation tonometer. At each of these visits, IOP measurement was performed at 0800, 1000 and 1600 hours. At each IOP assessment time point during a visit, 2 consecutive IOP measurements were made. If these 2 measurements differed by ≤2 mmHg, then the average of the 2 IOP values was recorded. If the 2 measurements differed by >2 mmHg, then a third measurement was obtained and the median of these 3 measurements was recorded. The IOP value for a visit (e.g., Week 4) was the mean of the values recorded at the 3 time points during the visit. For each participant, one "study eye" was identified for data summarization and analysis. The "study eye" was the eye with the higher (i.e., "worse") IOP at baseline, or if both eyes had the same baseline IOP value, the right eye was designated the "study eye." Percent reduction in IOP at Week 4 = ([baseline IOP value − Week 4 IOP value]/Baseline IOP value)*100.
Proportion of patients with≥25% reduction in IOP [ Time Frame: From baseline to Week 4 ] [ Designated as safety issue: No ]
Application of one drop of the medications in the morning and one drop in the evening for four weeks
Not Provided
Not Provided
 
Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)
A Phase III, Randomized, Active Comparator-Controlled, Four-Week, Double-Masked Clinical Trial to Compare the Efficacy and Safety of Preservative-Free MK-2452 (0.0015%) and Preservative-Free Timolol Maleate (0.5%) in Patients With Open-Angle Glaucoma or Ocular Hypertension in India

This study will test the hypothesis that preservative-free tafluprost (MK-2452) is non-inferior to preservative-free timolol maleate with respect to the diurnal intraocular pressure (IOP) change from baseline after 4 weeks of therapy in participants with open-angle glaucoma or ocular hypertension.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
  • Glaucoma
  • Ocular Hypertension
  • Drug: Preservative-Free Tafluprost or vehicle
    Preservative-free tafluprost (0.0015%) ophthalmic solution; Preservative-free vehicle ophthalmic solution (contains no active drug)
    Other Name: MK-2452
  • Drug: Preservative-Free Timolol maleate
    Preservative-free timolol maleate (0.5%) ophthalmic solution
    Other Name: Preservative-Free Timoptic
  • Experimental: Tafluprost
    One drop of preservative-free vehicle (contains no active drug) per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for four weeks. Morning dose with vehicle only allows blinding to match twice daily dosing of comparator arm.
    Intervention: Drug: Preservative-Free Tafluprost or vehicle
  • Active Comparator: Timolol
    One drop of preservative-free timolol maleate (0.05%) per eye twice daily (morning and evening) for four weeks.
    Intervention: Drug: Preservative-Free Timolol maleate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
190
May 2013
May 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Participant has been diagnosed with primary open-angle glaucoma, pigmentary glaucoma, capsular glaucoma/pseudoexfoliation, or ocular hypertension
  • Has been using ocular hypotensive medication on a stable treatment regimen for at least 30 days prior to screening, or is treatment-naive (has never used or has not used ocular hypotensive medication for the last 4 weeks prior to screening)
  • Able to discontinue all topical and/or systemic ocular hypotensive medication during the washout period (up to 4 weeks pre-study)
  • Best-corrected early treatment of diabetic retinopathy study (ETDRS) visual acuity of 20/80 or better in each eye
  • Willing and able to avoid wearing contact lenses from 4 weeks prior to dosing with study medication through 24 hours after final dosing
  • Willing and able to self-administer or has an able person available on a daily basis to assist with administration of study medications
  • Participant with reproductive potential must agree to remain abstinent (unless abstinence is not a locally acceptable method of contraception) or use highly effective methods of birth control (hormonal contraceptives, intrauterine device, diaphragm, condoms and vasectomy) within the projected duration of the study
  • Able to refrigerate study drug at home.

Exclusion Criteria:

  • Mean IOP >36 mmHg in either eye at screening
  • Unable to use study medication in the affected eye(s)
  • History of any inflammatory ocular surface disease or a history of anterior or posterior uveitis in either eye within 6 months prior to screening
  • History of retinal detachment, proliferative diabetic retinopathy, or any progressive retinal disease
  • Significant visual field loss or evidence of progressive visual loss within the last year
  • Intraocular surgery in either eye in the last 4 months
  • Any glaucoma surgery, refractive surgery, or penetrating keratoplasty in either eye
  • Currently on two or more anti-glaucoma medications (except Cosopt™ or its generic formulation)
  • Previously used tafluprost
  • History of cardiovascular disorder within 6 months of screening
  • History of bronchial asthma, wheezing, chronic obstructive pulmonary disease (COPD) or other pulmonary disease, abnormal chest x-ray, or has current active pneumonia.
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01254604
2452-002
No
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP